On June 9, 2025, Klotho Neurosciences, Inc. entered into a Stock Purchase Agreement for the sale of Series B Preferred stock totaling $500,000. Although the specific number of shares was not disclosed, these shares are convertible into the Company's Common Stock following SEC approval. The transaction was conducted without underwriters and no sales commissions were paid. The agreement was part of a private placement relying on an exemption from registration under the Securities Act of 1933.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-054373), on June 13, 2025, and is solely responsible for the information contained therein.